Bonus Biogroup (Israel) Performance
| BONS Stock | ILS 10.60 0.20 1.85% |
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Bonus Biogroup are completely uncorrelated. At this point, Bonus Biogroup has a negative expected return of -0.41%. Please make sure to confirm Bonus Biogroup's value at risk, accumulation distribution, and the relationship between the maximum drawdown and kurtosis , to decide if Bonus Biogroup performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Bonus Biogroup has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 16.1 M | |
| Total Cashflows From Investing Activities | -6.2 M |
Bonus |
Bonus Biogroup Relative Risk vs. Return Landscape
If you would invest 1,300 in Bonus Biogroup on September 15, 2024 and sell it today you would lose (240.00) from holding Bonus Biogroup or give up 18.46% of portfolio value over 90 days. Bonus Biogroup is generating negative expected returns and assumes 2.0113% volatility on return distribution over the 90 days horizon. Simply put, 17% of stocks are less volatile than Bonus, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Bonus Biogroup Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bonus Biogroup's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bonus Biogroup, and traders can use it to determine the average amount a Bonus Biogroup's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2056
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BONS |
Estimated Market Risk
| 2.01 actual daily | 17 83% of assets are more volatile |
Expected Return
| -0.41 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.21 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Bonus Biogroup is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bonus Biogroup by adding Bonus Biogroup to a well-diversified portfolio.
Bonus Biogroup Fundamentals Growth
Bonus Stock prices reflect investors' perceptions of the future prospects and financial health of Bonus Biogroup, and Bonus Biogroup fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bonus Stock performance.
| Return On Equity | -0.55 | |||
| Return On Asset | -0.0636 | |||
| Current Valuation | 169.66 M | |||
| Shares Outstanding | 1.17 B | |||
| Price To Book | 3.39 X | |||
| EBITDA | (88.03 M) | |||
| Cash And Equivalents | 3.6 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 6.28 M | |||
| Book Value Per Share | 0.12 X | |||
| Cash Flow From Operations | (39.84 M) | |||
| Earnings Per Share | (0.08) X | |||
| Total Asset | 104.32 M | |||
About Bonus Biogroup Performance
By analyzing Bonus Biogroup's fundamental ratios, stakeholders can gain valuable insights into Bonus Biogroup's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Bonus Biogroup has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bonus Biogroup has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Bonus BioGroup Ltd., a biotechnology company, develops technology solutions to generate tissue-regenerating bone grafts. Bonus BioGroup Ltd., formerly known as Oceana Advanced Industries Ltd., was founded in 1981 and is based in Haifa, Israel. BONUS BIOGROUP is traded on Tel Aviv Stock Exchange in Israel.Things to note about Bonus Biogroup performance evaluation
Checking the ongoing alerts about Bonus Biogroup for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bonus Biogroup help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bonus Biogroup generated a negative expected return over the last 90 days | |
| Bonus Biogroup has accumulated 6.28 M in total debt. Bonus Biogroup has a current ratio of 0.34, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Bonus Biogroup until it has trouble settling it off, either with new capital or with free cash flow. So, Bonus Biogroup's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bonus Biogroup sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bonus to invest in growth at high rates of return. When we think about Bonus Biogroup's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (90.08 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bonus Biogroup has accumulated about 3.6 M in cash with (39.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 50.0% of the company shares are held by company insiders |
- Analyzing Bonus Biogroup's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bonus Biogroup's stock is overvalued or undervalued compared to its peers.
- Examining Bonus Biogroup's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bonus Biogroup's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bonus Biogroup's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bonus Biogroup's stock. These opinions can provide insight into Bonus Biogroup's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Bonus Stock analysis
When running Bonus Biogroup's price analysis, check to measure Bonus Biogroup's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bonus Biogroup is operating at the current time. Most of Bonus Biogroup's value examination focuses on studying past and present price action to predict the probability of Bonus Biogroup's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bonus Biogroup's price. Additionally, you may evaluate how the addition of Bonus Biogroup to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |